PVRIG and neoplasm: Engagement of CD226 with its ligands PVRL2 and CD155 on target cells is essential for enhancing the anti-viral and anti-tumor functions of NK cells and T cells [39, 40], whereas CD96, TIGIT and PVRIG counterbalance CD226-dependent lymphocyte activation.